Cold Urticaria: Clinical Trials

2 trials for Cold Urticaria, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 2

Follow Cold Urticaria: new trials by email Literature Review of Cold Urticaria trials Research Report on Cold Urticaria

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
GTX-B001, Normal Saline - Healthy Subjects, Cold Urticaria
Phase 1RecruitingGranular Therapeutics Limited722025-10-062026-10-30
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
124I AT-01 - Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Phase 1RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)302025-09-102026-05-19

Narrower conditions

Amyloidosis (1)  ·  Chronic Inducible Urticaria (1)  ·  Cryopyrin-Associated Periodic Syndromes (1)  ·  Familial dermographism (1)  ·  Skin Diseases (1)  ·  Urticaria (1)

Broader conditions

Chronic Disease (2)  ·  Chronic Urticaria (2)  ·  Disease Attributes (2)  ·  Hypersensitivity (2)  ·  Hypersensitivity, Immediate (2)  ·  Immune System Diseases (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Skin Diseases, Vascular (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Chronic Inducible Urticaria (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Hereditary Autoinflammatory Diseases (1)

Interventions

Saline Solution (1)

Sponsors

Granular Therapeutics Limited (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

Germany (1)  ·  United States (1)

Top investigators

Sara Alehashemi, M.D. (1)

NIH funding

2025 (1)